Struggling Vaccines From Novartis Turn Into Sales Boon for Glaxo

  • Glaxo sees 2016 vaccine sales at nine times Novartis forecast
  • Meningitis shot Bexsero being studied as gonorrhea prevention

Outbreaks of the meningitis B disease in the U.S., along with the social-media frenzy that followed the death of a British toddler, have helped propel sales of GlaxoSmithKline Plc’s vaccine well past initial projections for its use.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.